GlassScriptPhysician profile
Cathy G Clark
NPI 1215009758
$1,434.73
in general payments reported to CMS, 2019-2025
23 companies · $319 in 2025
The $319 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $355 · 2022: $186 · 2023: $370 · 2024: $204 · 2025: $319.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $704 · Education: $189.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $704.37 |
| Education | $188.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $398.69 | 2021-2025 | Jakafi |
| Axsome Therapeutics, INC. | $143.09 | 2025 | Symbravo |
| Merck Sharp & Dohme LLC | $123.21 | 2021-2022 | |
| Janssen Biotech, INC. | $75.92 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $73.56 | 2021-2022 | |
| Amgen INC. | $58.74 | 2021-2025 | Repatha, Otezla, Repatha |
| Novartis Pharmaceuticals Corporation | $58.35 | 2023-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $52.87 | 2024 | |
| Abbvie INC. | $48.66 | 2023 | |
| Lilly USA, LLC | $48.19 | 2021-2024 | Mounjaro |
| Novo Nordisk INC | $43.63 | 2023-2025 | Saxenda, Wegovy |
| Organon LLC | $43.27 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $32.54 | 2023 | Libtayo |
| Glaxosmithkline, LLC. | $32.27 | 2021-2023 | Trelegy Ellipta, Shingrix |
| Celgene Corporation | $28.84 | 2024 | Reblozyl |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $28.41 | 2021-2024 | |
| Dexcom, INC. | $26.46 | 2025 | Dexcom G6 Transmitter |
| Array Biopharma INC | $25.15 | 2023 | Mektovi, Braftovi |
| Adaptive Biotechnologies Corporation | $21.52 | 2023 | Clonoseq |
| Otsuka America Pharmaceutical, INC. | $21.51 | 2023 | Rexulti |
| Exelixis INC. | $18.49 | 2023 | Cabometyx |
| Astellas Pharma US INC | $17.78 | 2023 | Veozah |
| Irhythm Technologies, INC. | $13.58 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cathy Clark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.